Fragment screening to predict druggability (ligandability) and lead discovery success
Drug Discov Today
.
2011 Apr;16(7-8):284-7.
doi: 10.1016/j.drudis.2011.02.002.
Epub 2011 Feb 16.
Authors
Fredrik N B Edfeldt
1
,
Rutger H A Folmer
,
Alexander L Breeze
Affiliation
1
Discovery-Enabling Capabilities and Sciences, AstraZeneca R&D, S-43183 Mölndal, Sweden. Fredrik.Edfeldt@astrazeneca.com
PMID:
21315179
DOI:
10.1016/j.drudis.2011.02.002
No abstract available
Publication types
Review
MeSH terms
Drug Discovery / methods*
Drug Evaluation, Preclinical*
Drug Industry*
High-Throughput Screening Assays*
Humans
Ligands
Molecular Targeted Therapy*
Peptide Fragments / metabolism
Substances
Ligands
Peptide Fragments